Home / Intelligence

Type
  • All
  • Analyst Reports
  • Blog
  • Briefs
  • Case Studies
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers
Featured Topic
  • All
  • AIML
  • Analytics
  • APAC
  • Benchmarking
  • Biosimilars
  • CAR-T
  • Cell and Gene Therapy
  • Commercial Operations
  • Competitive Intelligence
  • Contract Analytics
  • Corporate Strategy
  • COVID-19
  • Customer Engagement
  • Data Management
  • Digital Therapeutics
  • Diversity
  • Emerging Life Sciences
  • Europe
  • Evidence Strategy (HEOR)
  • Field Force
  • Forecasting
  • Generative AI
  • Incentive Compensation
  • Inflation Reduction Act
  • Insights
  • International
  • LatAm
  • Launch and Brand Excellence
  • Learning and Development
  • Market Research
  • Marketing
  • Medical Affairs
  • MedTech
  • New Product Planning
  • NRDL
  • Omnichannel
  • Oncology
  • Patient Centricity
  • Patient Finding
  • Patient Services
  • Performance Tracking
  • Pricing and Access
  • Product Demos
  • Rare Disease
  • Real-World Evidence
  • Scientific Publications
  • Sustainability
  • Talent Acquisition and Retention
  • United States
  • Value Communication
Search
Robotic hand playing chess

White Papers

Predicting Winners: AI-Powered Portfolio Management

Can artificial intelligence and machine learning (AIML) be used to support portfolio decision-making across the life sciences industry? Not only can the latest AIML techniques identify the drivers of success and failure in commercialization, but Trinity Life Sciences’ AI algorithm accurately predicts revenue outcomes for >90% of U.S. drug launches, far exceeding the accuracy of Wall Street analyst consensus at the time of launch (<60%).

Read Now

Webinars

Goodbye Humira, Hello Future

Available On Demand

Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success. In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window. The life sciences industry now seeks to understand how the vision for commercial success will evolve while in parallel navigating new artificial intelligence (AI) and other general-purpose technologies (GPTs) technologies…

Watch Now

Blog

The Last Mega Blockbuster Drug: Goodbye Humira, Hello Future

Published April 21, 2023

Executive Summary Biosimilar versions of adalimumab have launched in the U.S., ending blockbuster therapy Humira’s lengthy market exclusivity and long-running commercial success. In parallel, in the creation of the Inflation Reduction Act (IRA), the U.S. joins Europe and other major markets in constraining the opportunity for medicines during their market exclusivity window. Trinity’s Take These events usher in a new era for the life sciences industry, necessitating new thinking around development and commercialization strategy. Historic reliance on the U.S. market…

Read Now

Webinars

Developing Innovative, Patient-centric Services Using the Holistic Patient Journey

Available On Demand

Ensuring that Patient Support Services (PSS) are inspired by the patient and accurately reflect their key areas of need is an important facet of a patient-centric approach. Come join Jennifer Parr, Partner and Head of Patient Services & Patient Centricity at Trinity and Clare Gora, Vice President & Head of Analytics Client Development at Trinity as they discuss designing optimized PSS from holistic, robust patient journeys that identify the critical patient pain points, gaps, unmet needs and moments of meaning.…

Watch Now

Webinars

Far From Routine: Performance Tracking as a Source of Powerful Insight

Available On Demand

Assessing the impact of market events, advocacy, promotion and messaging is a key focus for Marketing and Brand leaders in life sciences. Stakeholder-perception tracking research is an often-overlooked strategic and tactical input as brands look to optimize their commercial performance. Come join Lara Lyeth, a Principal in Trinity’s Performance Tracking CoE, as she hosts a lively discussion on performance tracking with special guests Viplav Shukla, an Associate Director in Trinity’s Performance Tracking CoE, Monte Smith, a Managing Director in Trinity’s Brand &…

Watch Now

Blog

Highlights of the 2022 National Reimbursement Drug List (NRDL) Negotiation Outcome

Published March 10, 2023

Executive summary 83 non-traditional Chinese medicines successfully entered the National Reimbursement Drug List (NRDL) for the first time. This is a >20% increase from the 2021 and 2020 NRDL updates, indicating the growing interest of both manufacturers and payers to ensure reimbursement for novel therapies in China. The percentage of products achieving NRDL inclusion within one year of regulatory approval continues to increase steadily, from 24% in 2020 to 53% in the 2022 update, keeping up the strong momentum of…

Read Now

Webinars

Payer Predictions: Evolution of the U.S. Digital Therapeutics Reimbursement Landscape

Available On Demand

The digital therapeutics (DTx) market is growing rapidly, but a lack of clarity around their reimbursement framework in the U.S. means that there is limited coverage. DTx developers— and pharmaceutical organizations seeking an integrated digital offering— are left to wonder how the payer landscape will evolve as they strategize for the future. Join Trinity Life Sciences’ MedTech and Evidence, Value, Access and Pricing experts as they explore what the future DTx reimbursement landscape might look like, drawing upon detailed first-hand…

Watch Now

Webinars

Trinity Patient Flow: Lunch and Learn

Available On Demand

Patient-level insights. Now. Getting the right therapies to the right patients Assessing competitive dynamics Maximizing the value of patient level data with dynamic cohort design and visualization tools Trinity Patient Flow is an integrated toolkit, built to enable self-serve patient analytics and liberate patient-level data. Any patient-level claims or EHR data can be leveraged–whether it’s internally managed, vendor accessed or pre-populated. Come join us for a virtual demo and discussion, where Rajeev Rangachari, Head of Product Engineering, Kevin Francis, Partner,…

Watch Now

Webinars

Confident Contracting: Optimize and Accelerate Key Decisions with Tech-Enabled Impact Projections

Available On Demand

Developing and refining U.S. contract strategy and contract design is challenging. One of the most critical hurdles is evaluating the holistic direct and indirect impacts of contract decisions across multiple scenarios at speed and with precision. Achieving that comprehensive view drives clear guidance to pricing decision-makers and avoids costly mistakes. Join Monica Martin De Bustamante—Senior Partner & Head of Evidence, Value, Access & Pricing (EVAP), John Greenaway—EVAP Partner and Jennifer Boyce—EVAP Engagement Manager as they discuss tips and Trinity’s best practices to…

Watch Now

Case Studies

Improving Targeting Precision and Field Force Direction through AIML-based Patient Finding

Background A global rare disease company was looking to improve targeting precision and support field team effectiveness Traditional targeting was non-viable due to the small size of the patient populations, complex disease recognition and diagnosis, and restrictive therapy eligibility criteria Attempts by a prior analytics partner to use rule-based alerts failed, and even after two years, no new patients had been identified Given the small number of patients in each indication, every new start is high value, both for the…

Read Now

Blog

From Customer Relationship Management to Providing Customers Quality Multi-Experience Engagements: What to Keep in Mind as You Embrace the Shift

Published March 2, 2023

Meet Melissa Leonhauser: Melissa has over 20 years of experience managing analytic solutions that support pharmaceutical brand teams. She has helped introduce and shape how pharmaceutical manufacturers use Real World Data to understand the patient journey and inform their decision making. I’m not sure if ‘multi-experience engagements’ is just the newest buzz phrase, but I like it. It’s similar to ‘omnichannel marketing’ but with a focus on the customer instead of your efforts, and I appreciate that nuance. Let’s break…

Read Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.